©The Author(s) 2026.
World J Immunol. Jan 8, 2026; 16(1): 111511
Published online Jan 8, 2026. doi: 10.5411/wji.v16.i1.111511
Published online Jan 8, 2026. doi: 10.5411/wji.v16.i1.111511
Figure 7 Diagrammatic illustration showing the anti-tumor activity of zingerone by reducing the expression of transforming growth factor-beta.
TGF-β: Transforming growth factor-beta; MAPK: Mitogen-activated protein kinases; TAK-1: Transforming growth factor-beta-activated kinase 1; JAK: Janus kinase.
- Citation: Singh B, Singh H, Kaur S, Singh B. Preclinical pharmacology studies of zingerone with special reference to potential therapeutic applications. World J Immunol 2026; 16(1): 111511
- URL: https://www.wjgnet.com/2219-2824/full/v16/i1/111511.htm
- DOI: https://dx.doi.org/10.5411/wji.v16.i1.111511